Nabriva, which is developing antibiotics for drug-resistant infections, has now raised more than $190m in total and will advance its lead candidate into Phase 3 studies.
Austria-based biotechnology company Nabriva Therapeutics closed a $120m series B round today featuring Novartis Venture Fund, a corporate venturing subsidiary of pharmaceutical firm Novartis.
The round was co-led by venture capital firm Vivo Capital and investment firm OrbiMed and featured EcoR1 Capital, Boxer Capital, HBM Partners, Phase4 Partners, Wellcome Trust and Global Life Science Ventures (GLSV).
Founded in 2006, Nabriva is developing a class of antibiotics called pleuromutilins to treat infections caused by multi-drug resistant pathogens.
The initial $50m tranche…
